What Does a Gleason Score of 6 Mean in Prostate Cancer?

A Gleason score of 6 is the lowest grade assigned to prostate cancer on biopsy, and it carries the most favorable prognosis of any prostate cancer diagnosis. Under the newer grading system adopted internationally in 2014, Gleason 6 is reclassified as Grade Group 1, a designation deliberately chosen to signal that this sits at the bottom of the scale rather than the middle. The biology behind Gleason 6 tumors is genuinely reassuring, but the diagnosis still raises practical questions about monitoring, the risk of undergrading, and what living with the label “cancer” actually means for day-to-day life.

Why the Number 6 Is Misleading

The Gleason scoring system adds two pattern grades together, each ranging from 1 to 5. In theory, scores could run from 2 (1+1) to 10 (5+5). In practice, pathologists almost never assign patterns 1 or 2 on modern biopsy specimens, so the lowest score you will actually see on a report is 6 (3+3). That makes Gleason 6 sound like a mid-range result on a scale of 2 to 10, which is alarming to anyone who hears it for the first time. It is not mid-range. It is the floor.

To fix this communication problem, the International Society of Urological Pathology introduced a five-tier Grade Group system. Gleason 3+3=6 became Grade Group 1, Gleason 3+4=7 became Grade Group 2, and so on up to Grade Group 5 for the highest scores. The explicit goal was to reduce overtreatment of slow-growing disease by making clear to patients that their cancer sits at the very lowest risk level.¹ Your pathology report may list both the Gleason score and the Grade Group. If you see “Gleason 6, Grade Group 1,” those are two names for the same thing.

What the Biology Says About Metastasis

The single most reassuring fact about true Gleason 6 disease is its relationship to spread. A review of roughly 14,000 radical prostatectomy specimens, all re-graded under the modern Gleason system, found zero lymph node metastases among men whose surgical pathology confirmed Gleason 6.² That is not “rare.” That is none, in a dataset large enough to be confident about the finding. It is one of the reasons some researchers have questioned whether Gleason 6 should even carry the word “cancer” at all.

Long-term surgical data tell a similar story. In a study of men who had their prostates removed and whose tumors were confirmed as organ-confined Gleason 6, no distant metastases and no prostate-cancer-specific deaths occurred over follow-up periods extending out to 22 years. The chance of even a biochemical recurrence (a rise in PSA suggesting the cancer might be returning) was about 1% at 15 years.³ These are numbers that would be enviable for almost any cancer diagnosis.

Active Surveillance as the Standard Approach

Because of this favorable biology, active surveillance has become the recommended management strategy for men with low-risk prostate cancer, including Gleason 6. Active surveillance is not the same as doing nothing. It means monitoring the cancer with regular testing and stepping in with treatment if the disease shows signs of becoming more aggressive. The central advantage is avoiding the side effects of surgery or radiation, which can include urinary incontinence and erectile dysfunction, without compromising long-term cancer-specific survival.⁴

Surveillance protocols vary between institutions, but they generally involve some combination of PSA blood tests every few months, periodic MRI scans of the prostate, and repeat biopsies at scheduled intervals. Some newer protocols use MRI-guided targeted biopsies rather than the traditional systematic approach, which improves the accuracy of ongoing monitoring.⁵ MRI combined with PSA density measurements is also being studied as a way to reduce the number of repeat biopsies men need to undergo while still catching any progression early.⁶

If at any point during surveillance the cancer is upgraded to a higher Gleason score or shows other signs of progression, treatment options such as surgery, radiation, or focal therapy remain available. Active surveillance is not a one-way door. It is a strategy for delaying or avoiding treatment in cancers that may never need it, while preserving the option to treat if things change.

The Upgrading Problem

Here is where the reassuring biology of Gleason 6 runs into a practical complication. A biopsy samples only small slivers of the prostate. It can miss higher-grade areas of cancer that sit in unsampled parts of the gland. When men diagnosed with Gleason 6 on biopsy go on to have their prostates surgically removed, the surgical specimen sometimes reveals a higher Gleason score. This is called upgrading, and it happens with uncomfortable frequency.

Studies report upgrading rates ranging from roughly a third to nearly 40% of cases. One study of 241 patients found that about 38% of biopsy Gleason 6 cancers were upgraded to Gleason 7 or higher at surgery, and these upgraded tumors were significantly more likely to show adverse features like extension beyond the prostate capsule.⁷ Another study put the figure at about 33%, identifying PSA levels and the percentage of cancer in biopsy cores as predictors of who would be upgraded.⁸

This does not mean that a third of Gleason 6 diagnoses are wrong in a dangerous way. Most upgrades go from 3+3=6 to 3+4=7, which is still a favorable-risk cancer. Upgrades to Gleason 8 or higher are uncommon. But the possibility of upgrading is the main reason active surveillance protocols include periodic re-biopsies and imaging rather than simply checking PSA levels indefinitely. Risk factors for upgrading include higher PSA density, larger prostate glands, fewer biopsy cores taken initially, and biopsies that did not use MRI-targeted techniques.⁹

MRI-targeted biopsies have improved the situation. When MRI guidance is added to traditional systematic biopsies, the initial diagnosis becomes more accurate. In one study, combining targeted and systematic biopsies confirmed Gleason 6 in about three-quarters of cases, upgraded roughly a fifth to Gleason 3+4=7, and found higher-grade disease in only about 3%.¹⁰ As MRI-targeted biopsy becomes more widely available, the gap between biopsy grade and true surgical grade is expected to narrow further.

What Pathologists Disagree About

Gleason grading is not a machine measurement. It is a judgment call made by a pathologist looking at tissue under a microscope. And pathologists do not always agree. The most contentious area involves distinguishing Gleason pattern 3 (the building block of a Gleason 6 score) from pattern 4 (which would push the score to 7). In a study of 266 European pathologists, smoothly rounded cribriform glands, a specific architectural pattern in prostate tissue, were called pattern 3 by 51% and pattern 4 by 49%.¹¹ That is essentially a coin flip on a distinction that can change a patient’s treatment path.

Even among subspecialty pathologists who focus specifically on prostate tissue, certain patterns remain difficult to classify consistently. Cribriform and glomeruloid patterns tend to generate reasonable agreement as pattern 4, but ill-formed and fused glandular patterns are much harder to call, with some experts categorizing them as pattern 3 and others as pattern 4.¹² When the amount of pattern 4 in a sample is small, agreement drops further. In small foci of Gleason 7, pathologists matched each other’s estimates of how much pattern 4 was present only about a third of the time exactly, and about three-quarters of the time within a 10% margin.¹³

What this means for you in practical terms: if your biopsy shows Gleason 6 and you are unsure, a second-opinion review by a subspecialist genitourinary pathologist is reasonable, especially if your treatment decision hinges on whether the score might be a borderline 7. Many academic medical centers offer this routinely for prostate biopsies.

Genomic Tests and Molecular Profiling

Gleason grading looks at the architecture of the cells. Genomic tests look at their molecular behavior. Even among cancers that look like Gleason 6 under the microscope, a small but real fraction show molecular signatures associated with more aggressive disease. One study using a validated genomic classifier found that a “small but not insignificant proportion” of Gleason 6 tumors harbored molecular features typically seen in cancers with metastatic potential.¹⁴ These tests, available commercially under names like Decipher, Oncotype DX Genomic Prostate Score, and Prolaris, are increasingly used to help decide between active surveillance and treatment, especially when other clinical features create uncertainty.

Genomic testing is not standard for every Gleason 6 diagnosis. It tends to be most useful when a man is on the fence between surveillance and treatment, when there are clinical features that suggest the biopsy may have undersampled the tumor, or when a patient’s other risk factors (age, PSA trajectory, family history) raise questions that the Gleason score alone does not resolve.

The Emotional Weight of a Cancer Diagnosis

Being told you have cancer and then being told not to treat it creates genuine psychological tension. Research confirms that anxiety is a real and predictable part of the active surveillance experience. In a large prospective study, about 29% of men on surveillance reported prostate-cancer-specific anxiety after one year. The encouraging finding is that this anxiety dropped steadily over time, roughly halving by about seven and a half years on surveillance.¹⁵

The main psychological barriers to accepting active surveillance include anxiety about forgoing immediate treatment, a sense of lost control, and inadequate information about why surveillance is safe.¹⁶ Longitudinal research, though, shows that fear of progression and general distress tend to decrease rather than increase over time, and only a small number of men abandon surveillance specifically because of anxiety.¹⁷ Structured education at the time of diagnosis, along with consistent communication from the clinical team during follow-up, appears to make a meaningful difference in how well men cope with the surveillance approach.

Should Gleason 6 Even Be Called Cancer?

Given the biology, a reasonable person might wonder why Gleason 6 carries the cancer label at all. Some researchers have proposed reclassifying Grade Group 1 prostate cancer as a non-cancerous condition, similar to how certain pre-cancerous thyroid and bladder lesions were renamed to reduce unnecessary treatment. The argument is that removing the word “cancer” would reduce the psychological burden, the financial cost of overtreatment, and the physical side effects that come from treating a disease that was never going to harm the patient.

The pathology community, however, is not on board. A survey of the Genitourinary Pathology Society found that about 82% of pathologists opposed removing the cancer label from Grade Group 1 disease, while only about 14% supported it.¹⁸ The opposition stems partly from the upgrading problem discussed earlier: if a biopsy calls something Gleason 6 but the true grade turns out to be higher in a meaningful fraction of cases, relabeling the biopsy result as “not cancer” could lead men to decline monitoring entirely. There is also a legal and insurance dimension. Patients might lose access to surveillance protocols or coverage for follow-up imaging if their diagnosis is no longer formally classified as cancer. The debate is ongoing, but for now, the cancer label stays.

Racial Disparities in Gleason 6 Outcomes

Active surveillance outcomes are not identical across all populations. Research has identified concerning differences for Black men with Gleason 6 prostate cancer. A large JAMA study found that Black patients with Gleason 6 disease had roughly twice the risk of dying from prostate cancer compared to non-Black patients, an elevated risk that was not seen in higher Gleason scores.¹⁹ A separate study found that Black men on active surveillance were significantly more likely to experience disease progression, with a 10-year cumulative progression rate of about 60% compared to about 48% for White men, and were more likely to be upgraded to a higher Gleason score over time.²⁰

The reasons are not fully settled. One possibility is biological: the cancers themselves may behave differently. Another is anatomical: Black men appear to have a higher prevalence of anterior prostate tumors, which sit in a location that traditional biopsy techniques tend to undersample, potentially leading to missed higher-grade disease.²¹ Some retrospective studies using equal-access databases have found comparable outcomes between Black and White men with the same clinical characteristics, suggesting that differences in healthcare access and biopsy quality may explain part of the gap. The conflicting data make this a genuinely unresolved question. What it means practically is that Black men diagnosed with Gleason 6 prostate cancer should discuss these disparities explicitly with their clinician, and may benefit from more intensive surveillance protocols that include MRI-targeted biopsies.

Lifestyle During Active Surveillance

Men on active surveillance often want to know whether diet, exercise, or other lifestyle changes can slow their cancer’s progression. The idea is biologically plausible: epidemiological research has long linked dietary factors to prostate cancer risk, and experimental data suggest that components of the diet may influence tumor behavior. Some researchers have hypothesized that lifestyle interventions could lengthen the period before treatment becomes necessary.²²

The evidence so far, however, is more modest than the enthusiasm. A recent systematic review found that lifestyle interventions during active surveillance appear feasible and can improve physical fitness, metabolic health, and self-reported quality of life. But the review could not confirm a consistent effect on the outcomes that matter most: biopsy upgrading, MRI-measured progression, or how long men can safely stay on surveillance before needing treatment.²³ Exercise, a healthy diet, and maintaining a reasonable weight are worth pursuing for their general health benefits and for the way they improve quality of life during what can be an anxious period. Framing them as cancer-slowing treatments, though, gets ahead of what the research can support right now.

When Gleason 6 Leads to Treatment Anyway

Despite the strong case for surveillance, some men with Gleason 6 will end up being treated. The most common reason is upgrading on a follow-up biopsy. If a repeat biopsy during surveillance reveals Gleason 3+4=7 or higher, the management conversation shifts. PSA velocity (how fast PSA is rising) and MRI findings can also trigger a move toward treatment even if the Gleason score itself has not changed.

A smaller group of men choose treatment upfront for personal reasons: the psychological burden of living with untreated cancer, a strong family history that heightens their concern, or practical considerations like the desire to address the cancer before a certain age or before other health conditions complicate future treatment options. Guidelines do not prohibit treatment for Gleason 6. They recommend surveillance as the preferred approach but acknowledge that patient preference and individual risk factors play a legitimate role in the decision.

When treatment does happen, options include radical prostatectomy (surgical removal of the prostate), radiation therapy (external beam or brachytherapy), and, increasingly, focal therapies that treat only the portion of the gland containing the tumor. Focal approaches aim to offer cancer control with fewer side effects than whole-gland treatment, though long-term data comparing them to surgery and radiation for this population are still maturing. For organ-confined Gleason 6 disease treated with surgery, the long-term outlook is extremely favorable: as noted earlier, recurrence is rare, and cancer-specific death in this group is effectively absent in the published data over periods as long as two decades.³